AR044983A1 - Solidos con capa de difusion modulada - Google Patents

Solidos con capa de difusion modulada

Info

Publication number
AR044983A1
AR044983A1 ARP040102322A ARP040102322A AR044983A1 AR 044983 A1 AR044983 A1 AR 044983A1 AR P040102322 A ARP040102322 A AR P040102322A AR P040102322 A ARP040102322 A AR P040102322A AR 044983 A1 AR044983 A1 AR 044983A1
Authority
AR
Argentina
Prior art keywords
diffusion layer
drug
solid
modulated
modulated diffusion
Prior art date
Application number
ARP040102322A
Other languages
English (en)
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of AR044983A1 publication Critical patent/AR044983A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Sólidos con capa de difusión modulada que incluyen un excipiente y una sal soluble de un fármaco básico poco soluble; una sal soluble de un fármaco ácido poco soluble; o un fármaco no ionizable poco soluble, que son útiles, por ejemplo, para el suministro mejorado de fármacos. Reivindicación 1: Un sólido con capa de difusión modulada que comprende una sal soluble de un fármaco básico que presenta una solubilidad de al menos 50 microgramos/ml en un fluido acuoso a pH 6 a 7 a 25° C y un excipiente seleccionado entre el grupo que consiste de excipientes ácidos, excipientes solubilizantes, y combinaciones de los mismos; en los cuales por lo menos a un valor de pH, la tasa de disolución intrínseca del sólido con capa de difusión modulada es por lo menos 10 % mayor que la tasa de disolución intrínseca de la sal de fármaco sola al mismo pH, y en los cuales las tasas de disolución se determinan a 25° C en agua a un pH de 1 a 7 empleando el método del disco rotatorio. Reivindicación 8: Una composición que comprende: un sólido con capa de difusión modulada de acuerdo con cualquiera de las reivindicaciones 1 7; y un inhibidor del crecimiento de los cristales. Reivindicación 11: Un método para aumentar la biodisponibilidad de un fármaco que comprende proporcionar un sólido con capa de difusión modulada de acuerdo con cualquiera de las reivindicaciones 1 a 7. Reivindicación 12: Un método para preparar un sólido con capa de difusión modulada de acuerdo con cualquiera de la reivindicaciones 1, 4 y 7, el método que comprende preparar partículas que incluyen una sal soluble de un fármaco básico que presenta una solubilidad de al menos 50 microgramos/ml en un fluido acuoso a pH 6 a 7 a 25° C y un excipiente seleccionado entre el grupo que consiste de excipientes ácidos, excipientes solubilizantes y combinaciones de los mismos.
ARP040102322A 2003-07-01 2004-07-01 Solidos con capa de difusion modulada AR044983A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48420503P 2003-07-01 2003-07-01

Publications (1)

Publication Number Publication Date
AR044983A1 true AR044983A1 (es) 2005-10-12

Family

ID=34062033

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102322A AR044983A1 (es) 2003-07-01 2004-07-01 Solidos con capa de difusion modulada

Country Status (9)

Country Link
US (1) US20050042291A1 (es)
EP (1) EP1643948A1 (es)
JP (1) JP2007527394A (es)
AR (1) AR044983A1 (es)
BR (1) BRPI0412190A (es)
CA (1) CA2531116A1 (es)
MX (1) MXPA06000178A (es)
TW (1) TW200514576A (es)
WO (1) WO2005004763A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60234812D1 (de) 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
US8486452B2 (en) * 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
US20130203759A1 (en) * 2010-04-09 2013-08-08 Faranak Nikfar ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT
DE102011113749A1 (de) * 2011-09-14 2013-03-14 Aicuris Gmbh & Co. Kg Sulfonsäuresalze Heterocyclylamid-substituiertr Imidazole
CN110292575B (zh) * 2011-10-18 2022-05-13 株式会社AskAt 药物组合物
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
US20220339413A1 (en) * 2019-11-12 2022-10-27 W. L. Gore & Associates, Inc. Drug coated balloon

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4028772A (en) * 1971-04-02 1973-09-27 Merck & Co., Inc Chemical processes
US4355091A (en) * 1980-08-25 1982-10-19 Polaroid Corporation Polymeric neutralizing layer with temporary crosslinks from an organo-metallic crosslinking agent
IT1255792B (it) * 1992-08-05 1995-11-16 Bayer Italia Spa Composizioni farmaceutiche per la somministrazione orale di diidropiridine in forma di bevanda
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
ZA984514B (en) * 1997-05-29 1998-11-30 Merck & Co Inc Hiv protease inhibitor
ATE349203T1 (de) * 1998-06-11 2007-01-15 Pharmacia & Upjohn Co Llc Delavirdin tablettenformulierung
DK1163234T3 (da) * 1999-03-24 2006-02-27 Scherer Technologies Inc R P Farmaceutiske formuleringer med forbedret vandoplöselighed
YU43702A (sh) * 1999-12-23 2004-11-25 Pfizer Products Inc. Farmaceutske kompozicije koje obezbeđuju povećanje koncentracije leka
MXPA03011784A (es) * 2001-06-22 2004-04-02 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.

Also Published As

Publication number Publication date
US20050042291A1 (en) 2005-02-24
CA2531116A1 (en) 2005-01-20
MXPA06000178A (es) 2006-04-11
EP1643948A1 (en) 2006-04-12
JP2007527394A (ja) 2007-09-27
WO2005004763A1 (en) 2005-01-20
TW200514576A (en) 2005-05-01
BRPI0412190A (pt) 2006-08-22

Similar Documents

Publication Publication Date Title
ECSP055938A (es) Formulaciones farmaceuticas liquidas de palonosetron
CO6150131A2 (es) Sistema de liberacion controlada y metodo para fabricarlo
CO5560580A2 (es) Formulaciones de sucralosa para disumular sabores desagradables
CY1105771T1 (el) Φαρμακευτικες συνθεσεις εφαρμογης στον βλεννογονο
WO2005065646A3 (en) Novel drug compositions and dosage forms
WO2007056205A3 (en) Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
CL2010000816A1 (es) Formulacion adecuada para administracion subcutanea que comprende al menos 100 mg/ml de ctlaig, un azucar, y un portador acuoso farmaceuticamente estable; articulo de fabricacion que comprende al menos un recipiente que contiene la formulacion antes mencionada. (divisional solicitud n° 3597-06)
WO2002053100A3 (en) Pharmaceutical dosage form for oral administration of low molecular weight heparin
ES2531215T3 (es) Sistemas de administración de fármacos que comprenden un agente de bloqueo selectivo de la serotonina 5-HT3 débilmente básico y ácidos orgánicos
ATE493973T1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
AR068302A1 (es) Peptidos para vacunas para canceres que expresan antigenos asociados con tumores
UY27273A1 (es) Solución oral de arilpiprazol
AR038947A1 (es) Suspension oral de sabor agradable y metodo
ATE359779T1 (de) Selbstemulgierende systeme zur abgabe von taxoiden
WO2009066146A3 (en) Stable solutions of sparingly soluble actives
BG107347A (bg) Висококонцентрирани стабилни разтвори на мелоксикам
ES2720954T3 (es) Formulaciones estabilizadas de estatina
AR063538A1 (es) Tratamiento de la enfermedad de parkinson
CO6491061A2 (es) Formulacion de omeprazol farmaceutica estable para administracion oral
IT1314185B1 (it) Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
ES2344730T3 (es) Composicion farmacologica para administracion nasal de fentanilo.
ES2531241T3 (es) Composición farmacéutica líquida estable a base de trazodona
NO20025277D0 (no) Farmasöytisk administreringsform for peptider, dens fremstilling samt anvendelse
AR041945A1 (es) Sistema terapeutico multicapa de administracion a traves de las mucosas
PE20070377A1 (es) Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol

Legal Events

Date Code Title Description
FA Abandonment or withdrawal